ACW positive XanaMIA Data Monitoring Committee meeting
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The independent committee reviewed safety data from trial participants and concluded that the trial should proceed as planned. The next meeting will evaluate both safety and efficacy futility using unblinded data from participants.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- ACW September 2025 quarterly activity report & Appendix 4C
- ACW confirms eligibility for further $1.9m RDTI
- ACW achieves early screening closure for XanaMIA trial
- ACW receives initial $5.5m R&D tax incentive rebate
- Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer’s disease
Later from Actinogen Medical
- ACW XanaMIA trial fully enrolled with 246th participant
- Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial
- Actinogen secures $4.3m of non-dilutive R&D tax funding
- Trading Halt
- ACW positive XanaMIA Interim Analysis outcome
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical